摘要
青光眼滤过手术成功主要取决于滤过通道的瘢痕化反应.目前常用的抗代谢药物丝裂霉素C（MMC）和5-氟尿嘧啶（5-FU）仍存在较多的术后并发症.血管内皮生长因子（vascular endothelial growth factor,VEGF）在促进血管生成、创伤愈合、瘢痕形成中具有重要作用.抗VEGF药物能与VEGF受体结合,使VEGF的生物活性失效,抑制血管内皮细胞有丝分裂,减少血管通透性,从而阻断新生血管的形成.近年来贝伐单抗（bevacizumab）针对抗青光眼滤过术瘢痕化形成的研究较多,本文就VEGF的特性及其对伤口愈合反应的影响,通过玻璃体腔注射、前房注射、结膜下给药或滴眼等途径单独应用贝伐单抗或与MMC、5-FU联合应用的动物实验和临床研究结果做一综述.
The success of glaucoma filtration surgery mainly depends on the scar reaction of filtration channel.The application of antimetabolites such as mitomycin C （MMC） and 5-fluorouracil （5-FU） can reduce filtration channel scar formation.But they still can result in a series of complications：widespread cell death and apoptosis,postoperative hypotony,thin-walled bleb,bleb leakage even endophthalmitis.How to improve the success rate of filtration surgery and reduce the postoperative complications are always concerned.Vascular endothelial growth factor （VEGF） plays an important role in promote angiogenesis,wound healing and scar formation.Recently,there are a lot of studies about using anti-VEGF drug bevacizumab in the antifibotics for glaucoma surgery.This is a review about the characteristics of the VEGF,its effect on wound healing response,animal experiments and clinical studies of the application of bevacizumab alone or combines with MMC or 5-FU by way of intravitreous,subconjuctival or eyedrops during glaucoma filtration surgery.
出处
《国际眼科纵览》
2014年第5期300-304,共5页
International Review of Ophthalmology
